Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 3/20 | 0.54 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | GPR3 | P46089 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730993 | 0.92 | HRH3 (0.53) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL4401285 | 0.89 | HRH3 (0.59) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL14013426 | 0.85 | P2RY6 (0.67) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL4407993 | 0.85 | HRH3 (0.56) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL18089788 | 0.83 | P2RY6 (0.58) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL21124663 | 0.83 | GBA1 (0.56) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL4435583 | 0.82 | ESR1 (0.58) | CA12CA1CA2CA9SLC5A2 | |
| SCHEMBL14365817 | 0.82 | P2RY6 (0.56) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL21125050 | 0.82 | P2RY6 (0.58) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL12635290 | 0.82 | HRH3 (0.51) | HRH3CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-04-06 | — | — | US | disclosed |
| US-9416353-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150125924-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2015-05-07 | — | — | US | disclosed |
| US-8779221-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120330001-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | PROMEGA CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-8202700-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110207195-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | PROMEGA CORPORATION (US) | 2011-08-25 | — | — | US | disclosed |
| US-7935803-B2 | Expression vector comprising nucleotide sequences coding dehalogenase for use as tool to enhance labeling of biomolecules | PROMEGA CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935803-B2 | Expression vector comprising nucleotide sequences coding dehalogenase for use as tool to enhance labeling of biomolecules | PROMEGA CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7888086-B2 | mutant hydrolase forms stable bond with dehalogenase substrate; beta-lactamases; fusion proteins; cell labelling; tissue target therapy | PROMEGA CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888086-B2 | mutant hydrolase forms stable bond with dehalogenase substrate; beta-lactamases; fusion proteins; cell labelling; tissue target therapy | PROMEGA CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090098627-A1 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090098627-A1 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20080274488-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080274488-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-7429472-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2008-09-30 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | HRH3 2407/4885CA12 4286/4885CA1 3873/4885 |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | WASF2, NOTUM, YIPF5 | HRH3 2407/4885CA12 4286/4885CA1 3873/4885 |
| US-20120330001-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | HDHD5, DDT, DDAH1 | HRH3 951/4885CA12 1929/4885CA1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.